Advertisement
  • Loading metrics

NTD and NCD Co-morbidities: The Example of Dengue Fever

  • Priyanka Mehta,

    Affiliation Rice University, Houston, Texas, United States of America

  • Peter J. Hotez

    hotez@bcm.edu

    Affiliations Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development, National School of Tropical Medicine at Baylor College of Medicine, Houston, Texas, United States of America, Department of Biology, Baylor University, Waco, Texas, United States of America, James A Baker III Institute for Public Policy, Rice University, Houston, Texas, United States of America, Scowcroft Institute of International Affairs, Bush School of Government and Public Service at Texas A&M University, College Station, Texas, United States of America

    ORCID http://orcid.org/0000-0001-8770-1042

NTD and NCD Co-morbidities: The Example of Dengue Fever

  • Priyanka Mehta, 
  • Peter J. Hotez
PLOS
x

Recent findings of paradoxically high endemicity of neglected tropical diseases (NTDs) among populations living in the Group of 20 (G20) countries could portend high rates of these diseases among patients with underlying non-communicable diseases (NCDs), with resultant co-morbidities.

Today, the G20 countries, together with Nigeria, account for a surprising burden of the world’s NTDs, including approximately one-half of the major helminth infections and almost two-thirds or more of dengue, leprosy, Chagas disease, and leishmaniasis [1,2] as well as tuberculosis [3]. This finding has led to evidence of widespread neglected diseases among the poor who live in proximity to wealth, a concept that has been termed “blue marble health” [13].

Additional evidence that 70% of NCDs are also found in the G20 countries and Nigeria [4] suggests the possibility that we should find significant geographic overlap between NTDs and NCDs, especially in the largest middle-income countries such as Brazil, India, Indonesia, Mexico, and China. Ultimately, we can expect to see NTDs occurring among patients with underlying NCDs, and it will be of interest to determine whether unique co-morbidities arise as a result of such a clinical scenario.

Dengue and NCDs

Dengue fever represents a potentially important example of an NTD now rapidly emerging or re-emerging among the G20 countries. According to the Global Burden of Diseases, Injuries, and Risk Factors 2013 study (GBD 2013), the incidence of dengue has increased an astounding 610.87% between 1990 and 2013 [5] with up to 390 million cases now occurring annually [6]. The largest number of cases of dengue is found in South Asia, especially India and Bangladesh, as well as in Southeast Asia—Indonesia, China, Philippines, Vietnam, Thailand—and in Brazil and Mexico in the Americas [6]. These same countries also account for some of the highest deaths resulting from NCDs, including diabetes, cardiovascular disease, cancer, and chronic obstructive pulmonary disease [4]. The literature on dengue co-morbidities with NCDs in Asia and the Americas is still in a relatively nascent stage, but it is growing. There is evidence that dengue exacerbates the effects of NCDs and vice versa (Box 1).

Box 1. Major Co-morbidities Affecting Clinical Outcomes of Dengue Fever, DHF, and DHS

Underlying co-morbidities
  1. Diabetes Mellitus
  2. Hypertension
  3. Allergies (possibly associated with steroid use)
Co-morbidities that complicate dengue
  1. Renal failure
  2. Myocarditis/Pericarditis

Diabetes and Hypertension: NCDs That Worsen Clinical Outcomes in Dengue Patients

In the Lahore dengue epidemic of 2011, 60% of dengue patients who died suffered from at least one co-morbid condition, especially diabetes mellitus and hypertension or diabetes with hypertension [7]. These same co-morbidities were found to be important risk factors for death in other dengue epidemics [811]. Indeed, these two NCDs stand out for their impact on dengue fever patients, including those with dengue shock syndrome (DSS) or dengue hemorrhagic fever (DHF).

Diabetes

Dengue patients with pre-existing diabetes mellitus are reported 1.78 to 2.8 times more likely to develop DHF and tend to have more severe thrombocytopenia, which is often used as a measure of dengue infection severity [8,10,12,13]. Diabetes was associated with DHF and DSS during the epidemic in Havana, Cuba, in 1981 [14,15]. The physiologic mechanisms underlying this observation need to be further investigated. However, it has been suggested that patients with diabetes exhibit disrupted endothelial dysfunction, possibly because their altered metabolic state triggers the release of inflammatory cytokines—the resultant increase in endothelial permeability (vascular leak) may exacerbate third space fluid shifts characteristic of DHF [12,16]. As a result, dengue patients with co-morbid diabetes require longer hospitalizations and more medical attention than DHF patients without diabetes [8,10]. Uncontrolled diabetes is also associated with increased mortality; in a study from Kerala State, India, these patients are 26 times more likely to die as a result of their condition [11].

Hypertension

A similar mechanism may explain why dengue patients with hypertension (or diabetes with hypertension) face a 1.6 to 2.16 times greater risk of progressing to DHF [10,17]. Hypertensive individuals often have elevated C-reactive protein levels in the blood, which increases capillary permeability and risk of coagulopathy [17]. In Kerala State, India, patients with underlying hypertension were found to be 44 times more likely to die from dengue [11].

Other co-morbidities

Underlying chronic kidney disease and ischemic heart disease have also been linked to DHF and poor clinical outcome [8], although possibly these factors are also associated with diabetes and hypertension. Other interesting risk factors for severe dengue, DHF, or DSS include underlying allergies [12,17], autoimmune disorders [18], bronchial asthma [14], and sickle cell disease [14,19]. In at least one study, the steroids used to treat allergies might have been an important factor, as those patients exhibited a 2.94 odds ratio of DHF [12]; however, skin allergy itself was found to be a risk factor in a case-controlled study from six cities in Brazil [17].

Renal Disease, Myocarditis, and Other Co-morbidities Arising from Dengue Fever

Conversely, certain co-morbidities arise as a result of dengue infection. One such disorder, acute renal failure (ARF), often occurs as a result of multi-organ dysfunction caused by severe forms of dengue, including DHF and DSS, occurring in approximately 2%–5% of the cases [20]. While most renal disorders associated with dengue are resolved without therapy, ARF significantly increases the chances of death [20]. Furthermore, in about 15% of patients, dengue was shown to cause cardiac disease (elevation of cardiac biomarkers), mostly with a clinical picture consistent with myocarditis or pericarditis [9,21], possibly due to direct viral invasion of the cardiac tissue [22]. Another condition noted to arise in association with dengue and DHF is a thickened gall bladder [8]. Some findings also suggest that worsening of chronic illness may be responsible for the high fatality rate seen in dengue patients with co-morbid conditions rather than worsening of the dengue itself [9]. In adult lymphoblastic leukemia patients, dengue infection often leads to febrile neutropenia and adds to the myelosuppression of chemotherapy, resulting in poor outcomes [23].

Concluding Statement

Research on co-morbid conditions and their influence on the progression of dengue fever has yielded valuable insights. Reducing case fatality rates through management of risk factors, especially diabetes and hypertension, and dengue complications, especially renal and heart disease, provide important opportunities to improve clinical outcomes. Through heightened understanding of the complex interactions between dengue and several co-morbid NCDs, we can determine how to prioritize target populations for interventions and effectively allocate resources for treatment. A key example is the pipeline of dengue vaccines now under development [24], which could be introduced or prioritized for individuals with underlying diabetes and hypertension.

Dengue and its co-morbidities represent an important example of the overlap between NTDs and NCDs, especially among the poor. However, there is urgency to better understand co-morbidity pathogenesis in humans as well as to identify additional examples of NCD interactions among the 17 NTDs now recognized by the World Health Organization.

References

  1. 1. Hotez PJ (2015) Blue Marble Health Redux: Neglected Tropical Diseases and Human Development in the Group of 20 (G20) Nations and Nigeria. PLoS Negl Trop Dis 9: e0003672. doi: 10.1371/journal.pntd.0003672. pmid:26218831
  2. 2. Hotez PJ. NTDs V.2.0: "blue marble health"—neglected tropical disease control and elimination in a shifting health policy landscape (2013) PLoS Negl Trop Dis 7: e2570. doi: 10.1371/journal.pntd.0002570. pmid:24278496
  3. 3. Hotez PJ (2015) Blue marble health and "the big three diseases": HIV/AIDS, tuberculosis, and malaria. Microbes Infect 17: 539–41. doi: 10.1016/j.micinf.2015.05.004. pmid:26003523
  4. 4. Hotez PJ, Peiperl L. Noncommunicable Diseases: A Globalization of Disparity? (2015) PLoS Med. 2015 12:e1001859. doi: 10.1371/journal.pmed.1001859. pmid:26218734
  5. 5. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) Lancet 386:743–800. doi: 10.1016/S0140-6736(15)60692-4. pmid:26063472
  6. 6. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global distribution and burden of dengue. Nature 496:504–7. doi: 10.1038/nature12060. pmid:23563266
  7. 7. Saqib M, Rafique I, Bashir S, Salam AA (2015) A retrospective analysis of dengue fever case management and frequency of co-morbidities associated with deaths. BMC Research Notes 7: 205.
  8. 8. Mallhi TH, Khan AH, Adnan AS, Sarriff A, Khan YH, Jummaat F (2015) Clinico-laboratory spectrum of dengue viral infection and risk factors associated with dengue hemorrhagic fever: a retrospective study. BMC Infectious Diseases 15:399. doi: 10.1186/s12879-015-1141-3. pmid:26423145
  9. 9. Sam S. Omar SFS, Teoh T, Abd-Jamil J, AbuBakar S. (2013) Review of Dengue Hemorrhagic Fever Fatal Cases Seen Among Adults: A Retrospective Study. PLoS Negl Trop Dis 7:e2194. doi: 10.1371/journal.pntd.0002194. pmid:23658849
  10. 10. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, et al. (2012) Diabetes with Hypertension as Risk Factors for Adult Dengue Hemorrhagic Fever in a Predominantly Serotype 2 Epidemic: A Case Control Study. PLoS Negl Trop Dis 6:e1641. doi: 10.1371/journal.pntd.0001641. pmid:22563519
  11. 11. Karunakaran A, Ilyas WM, Sheen SF, Jose NK, Nujum ZT (2014) Risk factors of mortality among dengue patients admitted to a tertiary care setting in Kerala, India. Journal of Infection and Public Health 7:114–120. doi: 10.1016/j.jiph.2013.09.006. pmid:24290074
  12. 12. Figueiredo MA, Rodrigues LC, Barreto ML, Lima JW, Costa M, et al. (2010) Allergies and Diabetes as Risk Factors for Dengue Hemorrhagic Fever: Results of a Case Control Study. PLoS Negl Trop Dis 4: e699. doi: 10.1371/journal.pntd.0000699. pmid:20532230
  13. 13. Chen C, Lee M, Lin K, Hsu W, Lee Y, et al. (2015) Diabetes Mellitus Increases Severity of Thrombocytopenia in Dengue-Infected Patients. Int J Molecular Sci 2015 16: 3820–3830.
  14. 14. Bravo JR, Guzman MG, Kouri GP (1987) Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for degue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 81(5): 816–20. pmid:3450004
  15. 15. Kouri GP, Guzman MG, Bravo JR (1987) Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans R Soc Trop Med Hyg 81(5): 821–3. pmid:3450005
  16. 16. Limonta D, Torres G, Capo V, Gusman MG (2008) Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient. Diab Vasc Dis Res 5(3) 213–4. doi: 10.3132/dvdr.2008.034. pmid:18777495
  17. 17. Teixeira MG, Paixao ES, Costa M, Cunha RV, Pamplona L, et al. (2015) Arterial Hypertension and Skin Allergy Are Risk Factors for Progression from Dengue to Dengue Hemorrhagic Fever: A Case Control Study. PLoS Negl Trop Dis. 9: e0003812. doi: 10.1371/journal.pntd.0003812. pmid:25996882
  18. 18. Garcia G, Gonzalez N, Perez AB, Sierra B, Aguirre E, Rizo D, Izquierdo A, Sanchez L, Diaz D, Lezcay M, Pacheco B, Hirayama K, Guzman MG (2011) Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis 15(1): e38–43. doi: 10.1016/j.ijid.2010.09.008. pmid:21112804
  19. 19. Limonta D, González D, Capó V, Torres G, Pérez AB, Rosario D, Roche-Rodriguez R, Alvarez M, Guzmán MG (2009) Fatal severe dengue and cell death in sickle cell disease during the 2001–2002 Havana dengue epidemic. Int J Infect Dis 13(2):e77–8. doi: 10.1016/j.ijid.2008.06.028. pmid:18849178
  20. 20. Lizarraga KJ, Nayer A (2014) Dengue-associated kidney disease. J Nephropathology 3: 57–62. doi: 10.12860/jnp.2014.13. pmid:24772398
  21. 21. Miranda CH, Borges MD, Matsuno AK, Vilar FC, Gali LG, et al. (2013) Evaluation of Cardiac Involvement During Dengue Viral Infection. Clin Infect Dis 57: 812–819. doi: 10.1093/cid/cit403. pmid:23784923
  22. 22. Miranda CH, Borhes MC, Schmidt A, Pazin-Filho A, Rossi MA, et al. (2013) A case presentation of a fatal dengue myocarditis showing evidence for dengue virus-induced lesion Eur Heart J Acute Cardiovasc Care 2: 127–30. doi: 10.1177/2048872613475889. pmid:24222821
  23. 23. Jain H, Sengar M, Menon H, Dangi U, Biswas S, Chandrakanth MV (2014) Dengue fever as a cause of febrile neutropenia in adult acute lymphoblastic leukemia: A single center experience. Hematol Oncol Stem Cell Ther 7: 125–126. doi: 10.1016/j.hemonc.2014.04.002. pmid:24793316
  24. 24. Schwartz LM, Halloran ME, Durbin AP, Longini IM Jr. (2015) The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine 33: 3293–8. doi: 10.1016/j.vaccine.2015.05.010. pmid:25989449